TheraRadar
← Back
Data updated: May 24, 2026

CHECKPOINT THERAPEUTICS INC

Biotech

CHECKPOINT THERAPEUTICS INC is a biotechnology company focused on Immunology, Oncology, Dermatology.

2024
Since
1
Drugs
-
Trials
1
New Drugs (2yr)
Novel Drugs (2024):
1 Novel Approvals

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Immunology 75%
0 drugs Phase 3: 7 Phase 2: 7
Oncology 21%
1 drugs Phase 3: 1 Phase 1: 2
Dermatology 4%
0 drugs Phase 2: 1

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

8
Phase 3
8
Phase 2
2
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • UNLOXCYT leads revenue
  • Drug-level revenue analysis

Trial Catalysts

  • Immunology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling